{"id":"switched-from-prograf-to-envarsus","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Tremor"},{"rate":"15-40","effect":"Headache"},{"rate":"30-50","effect":"Hypertension"},{"rate":"25-40","effect":"Nephrotoxicity/renal dysfunction"},{"rate":"15-30","effect":"Hyperglycemia/new-onset diabetes"},{"rate":"20-40","effect":"Infection"},{"rate":"10-25","effect":"Nausea"},{"rate":"10-20","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL6068498","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus is a calcineurin inhibitor that prevents dephosphorylation of nuclear factor of activated T cells (NFAT), thereby suppressing T-cell proliferation and cytokine production. Envarsus® uses MeltDose® technology to provide once-daily extended-release delivery, improving bioavailability and reducing peak-to-trough fluctuations compared to immediate-release Prograf®, while maintaining equivalent immunosuppressive efficacy.","oneSentence":"Envarsus® is an extended-release formulation of tacrolimus that provides sustained immunosuppression by inhibiting calcineurin and blocking T-cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:23.774Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of organ rejection in adult patients receiving allogeneic kidney, heart, or liver transplants"}]},"trialDetails":[{"nctId":"NCT02882828","phase":"PHASE4","title":"PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2016-10","conditions":"Allograft","enrollment":134},{"nctId":"NCT01702207","phase":"PHASE4","title":"Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2012-10","conditions":"Immunosuppression, Cardiovascular Diseases, Kidney Transplantation","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"switched from Prograf® to Envarsus®","genericName":"switched from Prograf® to Envarsus®","companyName":"University Hospital, Limoges","companyId":"university-hospital-limoges","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Envarsus® is an extended-release formulation of tacrolimus that provides sustained immunosuppression by inhibiting calcineurin and blocking T-cell activation. Used for Prophylaxis of organ rejection in adult patients receiving allogeneic kidney, heart, or liver transplants.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}